Sector consensus Abbott Laboratories
Equities
ABT
US0028241000
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 110.25 USD | -0.27% |
|
-2.52% | -12.00% |
| Mar. 11 | Citigroup Adjusts Price Target on Abbott Laboratories to $136 From $140, Maintains Buy Rating | MT |
| Mar. 10 | MBX Biosciences, Inc. Appoints Karen Basbaum As Chief Business Officer | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | $133.33 | +20.61% | 24 | ||||||
| $111.69 | +24.25% | 26 | ||||||
| $410 | +16.41% | 13 | ||||||
| ¥27,771.43 | +1.19% | 14 | ||||||
| $197.15 | +20.3% | 13 | ||||||
| $85.85 | +26.64% | 26 | ||||||
| $281.25 | +26.64% | 8 | ||||||
| ¥2,956.15 | +44.7% | 13 | ||||||
| €234.29 | +41.65% | 14 | ||||||
| $102.65 | +11.94% | 23 | ||||||
| $318.36 | +36.15% | 14 | ||||||
| $354.4 | +48.76% | 25 | ||||||
| NZ$41.12 | +8.02% | 12 | ||||||
| $201.57 | +18.97% | 14 | ||||||
| $90.17 | +33.38% | 12 | ||||||
| $109.54 | +26.41% | 13 | ||||||
| $21.63 | +23.9% | 15 | ||||||
| $324 | +20.96% | 5 | ||||||
| $186.28 | +52.95% | 18 | ||||||
| Average | 1,785.83 | +26.52% | 16 | ||||||
| Weighted average by Cap. | 2,600.2 | +22.04% | 19 |
- Stock Market
- Equities
- ABT Stock
- Sector Abbott Laboratories
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
